LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $615 | $573 | $687 | $503 |
| % Growth | 7.2% | -16.6% | 36.6% | – |
| Cost of Goods Sold | $108 | $118 | $153 | $121 |
| Gross Profit | $507 | $456 | $534 | $381 |
| % Margin | 82.5% | 79.5% | 77.7% | 75.9% |
| R&D Expenses | $146 | $303 | $319 | $211 |
| G&A Expenses | $136 | $148 | $82 | $107 |
| SG&A Expenses | $391 | $428 | $333 | $273 |
| Sales & Mktg Exp. | $255 | $280 | $252 | $166 |
| Other Operating Expenses | $56 | $171 | $21 | $16 |
| Operating Expenses | $593 | $902 | $673 | $500 |
| Operating Income | -$86 | -$446 | -$139 | -$119 |
| % Margin | -14% | -77.7% | -20.3% | -23.7% |
| Other Income/Exp. Net | -$15 | -$9 | -$143 | -$113 |
| Pre-Tax Income | -$101 | -$455 | -$282 | -$232 |
| Tax Expense | -$1 | -$22 | $1 | $5 |
| Net Income | -$100 | -$433 | -$145 | -$237 |
| % Margin | -16.3% | -75.6% | -21.2% | -47.1% |
| EPS | -0.94 | -4.05 | -1.88 | -0.019 |
| % Growth | 76.8% | -115.4% | -10,062.2% | – |
| EPS Diluted | -0.94 | -4.05 | -1.88 | -0.019 |
| Weighted Avg Shares Out | 107 | 107 | 77 | 30 |
| Weighted Avg Shares Out Dil | 107 | 107 | 77 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $16 | $44 | $31 | $3 |
| Depreciation & Amortization | $37 | $42 | $37 | $31 |
| EBITDA | -$49 | -$369 | -$77 | -$67 |
| % Margin | -7.9% | -64.3% | -11.2% | -13.4% |